Aquestive Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company that leverages its proprietary PharmFilm technology to develop and commercialize orally administered drug delivery alternatives to invasive or inconvenient standard-of-care therapies. The company's commercial portfolio includes Suboxone (manufactured for Indivior), Sympazan (clobazam oral film), Ondif (ondansetron oral film), and Emylif (riluzole oral film). Aquestive's primary late-stage pipeline candidate is Anaphylm (dibutepinephrine) sublingual film, a non-device, needle-free oral epinephrine rescue medication designed for the emergency treatment of severe Type I allergic reactions, including anaphylaxis. Additionally, the company is advancing its AdrenaVerse platform, which includes AQST-108, a topical epinephrine gel being evaluated for dermatological conditions such as alopecia areata.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing regulatory filings for Anaphylm™ sublingual film outside the United States, specifically targeting submissions to Health Canada and the European Medicines Agency (EMA) using existing clinical data.
Expected impact: Establishes global market access and commercial footprint for the company's lead epinephrine prodrug candidate.
Developing AQST-108, a topical epinephrine gel utilizing the AdrenaVerse™ platform, for dermatological conditions such as alopecia areata.
Expected impact: Expands the pipeline beyond systemic rescue therapies into targeted, non-systemic dermatological treatments.
Refinancing the company's existing debt facility with a new $150 million facility managed by Oaktree Capital Management.
Expected impact: Eliminates $45 million in principal debt repayments over the next three years, lowers the interest rate, and provides financial flexibility to fund the potential launch of Anaphylm™.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides critical non-dilutive capital to support the commercial launch of Anaphylm™ upon FDA approval.
Terms: A $75 million strategic funding agreement, which was amended in March 2026 to extend the marketing approval deadline to June 30, 2027. Includes the issuance of a warrant to RTW for up to 375,000 shares at $4.00 per share and a commitment from RTW-affiliated funds to purchase at least $5 million of common stock.
Secures long-term scalable capital to support the company's growth and pre-commercialization infrastructure.
Terms: A new $150 million debt facility, with the first tranche drawn at closing to refinance existing debt, a second tranche available upon FDA approval of Anaphylm™, a third tranche of $25 million available upon achieving specified sales milestones, and a final tranche of up to $50 million available by mutual consent.